Positive Correlation Between the Density of Neuropeptide Y Positive Neurons in the Amygdala and Parameters of Self-Reported Anxiety and Depression in Mesiotemporal Lobe Epilepsy Patients

Biological Psychiatry

Volumn 66, Issue 5, 2009, Pages 433-440

  Frisch, Christian ^a   Hanke, Joachim ^b   Kleinerüschkamp, Sven ^a   Röske, Sandra ^a   Kaaden, Sabine ^b   Elger, Christian E ^a   Schramm, Johannes ^a   Yilmazer Hanke, Denis M ^c   Helmstaedter, Christoph ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Amygdala; anxiety; depression; human temporal lobe epilepsy; Neuropeptide Y

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; LAMOTRIGINE; NEUROPEPTIDE Y; OXCARBAZEPINE; TOPIRAMATE; VALPROIC ACID;

ADULT; AGED; AMYGDALOID NUCLEUS; ANTICONVULSANT THERAPY; ANXIETY; ARTICLE; BRAIN SIZE; CELL COUNT; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEMISPHERECTOMY; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MALE; MORBIDITY; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIVARY NUCLEUS; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SELF REPORT; TEMPORAL LOBE EPILEPSY; TEMPORAL LOBECTOMY;

ADOLESCENT; ADULT; AMYGDALA; ANTICONVULSANTS; ANXIETY; COHORT STUDIES; DEPRESSION; EPILEPSY, TEMPORAL LOBE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURONS; NEUROPEPTIDE Y; QUALITY OF LIFE;

EID: 68049139263     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.03.025     Document Type: Article

References (70)

1. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y-A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 (1982) 659-660
2. Fuxe K., Agnati L.F., Harfstrand A., Zini I., Tatemoto K., Pich E.M., et al. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 118 (1983) 189-192
3. Heilig M., and Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 19 (1987) 221-2311
4. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 38 (2004) 213-224
5. Berglund M.M., Hipskind P.A., and Gehlert D.R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med 228 (2003) 217-244
6. Flood J.F., Baker M.L., Hernandez E.N., and Morley J.E. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res 503 (1989) 73-82
7. Vezzani A., and Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: An endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides 38 (2004) 245-252
8. Jamali S., Bartolomei F., Robaglia-Schlupp A., Massacrier A., Peragut J.C., Regis J., et al. Large-scale expression study of human mesial temporal lobe epilepsy: Evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. Brain 29 (2006) 625-641
9. Furtinger S., Pirker S., Czech T., Baumgartner C., Ransmayr R., and Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 21 (2001) 5804-5812
10. Lurton D., and Cavalheiro E.D. Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy. Exp Brain Res 116 (1997) 186-190
11. Shannon H.E., and Yang L. Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models. Epilepsy Res 61 (2004) 49-62
12. Heilig M., Koob G.F., Ekman R., and Britton K.T. Corticotropin-releasing factor and neuropeptide Y: Role in emotional integration. Trends Neurosci 17 (1994) 80-85
13. Sajdyk T.J., Shekhar A., and Gehlert D.R. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 38 (2004) 225-234
14. Phelps E.A., and LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48 (2005) 175-187
15. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (2008) 997-1001
16. Sajdyk T.J., Vandergriff M.G., and Gehlert D.R. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368 (1999) 143-147
17. Sajdyk T.J., Fitz S.D., and Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 9 (2006) 21-28
18. Yilmazer-Hanke D.M., Faber-Zuschratter H., Linke R., and Schwegler H. Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high- and low-avoidance rats. Eur J Neurosci 15 (2002) 1206-1218
19. Yilmazer-Hanke D.M., Hantsch M., Hanke J., Schulz C., Faber-Zuschratter H., and Schwegler H. Neonatal thyroxine treatment: Changes in the number of corticotropin-releasing-factor (CRF) and neuropeptide Y (NPY) immunoreactive neurons and density of tyrosine hydroxylase positive fibers (TH) in the amygdala correlate with anxiety-related behavior of Wistar rats. Neuroscience 124 (2004) 283-297
20. Van Elst L.T., Woermann F.G., Lemieux L., Thompson P.J., and Trimble M.R. Affective aggression in patients with temporal lobe epilepsy: A quantitative MRI study of the amygdala. Brain 123 (2000) 234-243
21. Briellmann R.S., Hopwood M.J., and Jackson G.D. Major depression in temporal lobe epilepsy with hippocampal sclerosis: Clinical and imaging correlates. J Neurol Neurosurg Psychiatry 78 (2007) 1226-1230
22. Helmstaedter C., Sonntag-Dillender M., Hoppe C., and Elger C.E. Depressed mood and memory impairment in temporal lobe epilepsy as a function of focus lateralization and localization. Epilepsy Behav 5 (2004) 696-701
23. Hudson L.P., Munoz D.G., Miller L., McLachlan R.S., Girvin J.P., and Blume W.T. Amygdaloid sclerosis in temporal lobe epilepsy. Ann Neurol 33 (1993) 622-631
24. McDonald A.J., and Pearson J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci Lett 100 (1989) 53-58
25. Sosulina L., Meis S., Seifert G., Steinhauser C., and Pape H.C. Classification of projection neurons and interneurons in the rat lateral amygdala based upon cluster analysis. Mol Cell Neurosci 33 (2006) 57-67
26. Yilmazer-Hanke D.M., Wolf H.K., Schramm J., Elger C.E., Wiestler O.D., and Blümcke I. Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy. J Neuropathol Exp Neurol 59 (2000) 907-920
27. Wolf H.K., Aliashkevich A.F., Blümcke I., Wiestler O.D., and Zentner J. Neuronal loss and gliosis of the amygdaloid nucleus in temporal lobe epilepsy. Acta Neuropathol 93 (1997) 606-610
28. Pitkänen A., Tuunanen J., Kälviäinen R., Partanen K., and Salmenperä T. Amygdala damage in experimental and human temporal lobe epilepsy. Epilepsy Res 32 (1998) 233-253
29. Zentner J., Wolf H.K., Helmstaedter C., Grunwald T., Aliashkevich A.F., Wiestler O.D., et al. Clinical relevance of amygdala sclerosis in temporal lobe epilepsy. J Neurosurg 91 (1999) 59-67
30. Yilmazer-Hanke D.M., Faber-Zuschratter H., Blümcke I., Bickel M., Becker A., Mawrin C., et al. Axosomatic inhibition of projection neurons in the lateral nucleus of amygdala in human temporal lobe epilepsy: An ultrastructural study. Exp Brain Res 177 (2007) 384-399
31. Beck A.T., Rush A.J., Shaw B.F., and Emery G. Kognitive Therapie der Depressionen [cognitive therapy of depressions] (1981), Urban Schwarzenberg, Munich
32. Zung W.W. A rating instrument for anxiety disorders. Psychosomatics 12 (1971) 371-379
33. Cramer J.A., Perrine K., Devinsky O., and Meador K. A brief questionnaire to screen for quality of life in epielpsy: The QOLIE-10. Epilepsia 37 (1996) 577-582
34. Urbach H., Hattingen J., von Oertzen J., Luyken C., Clusmann H., Kral T., et al. MRI in the presurgical evaluation of patients with drug-resistant epilepsies. AJNR Am J Neuroradiol 25 (2004) 919-926
35. Morrison D.F. Multivariate Statistical Methods (1976), McGraw-Hill, New York
36. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1998), Lawrence Erlbaum, Hillsdale, New Jersey
37. Steer R.A., Kumar G., Ranieri W.F., and Beck A.T. Use of the Beck anxiety Inventory with adolescent psychiatric outpatients. Psychol Rep 76 (1995) 459-465
38. Steer R.A., Clark D.A., Beck A.T., and Ranieri W.F. Common and specific dimensions of self-reported anxiety and depression: The BDI-II versus the BDI-IA. Behav Res Ther 37 (1998) 183-190
39. Reuber M., Andersen B., Elger C.E., and Helmstaedter C. Depression and anxiety before and after temporal lobe epilepsy surgery. Seizure 13 (2004) 129-135
40. de Lanerolle N.C., Kim J.H., Williamson A., Spencer S.S., Zaveri H.P., Eid T., and Spencer D.D. A retrospective analysis of hippocampal pathology in human temporal lobe epilepsy: Evidence for distinctive patient subcategories. Epilepsia 44 (2003) 677-687
41. Thorsell A., Carlson K., Ekman R., and Heilig M. Behavioral and endocrine adaptation, and upregulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 29 (1999) 3003-3007
42. de Lange R.P., Wiegant V.M., and Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res 1212 (2008) 35-47
43. Mathé A.A., Husum H., El Khoury A., Jiménez-Vasquez P., Gruber S.H., Wörtwein G., et al. Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. Physiol Behav 9 (2008) 226-231
44. Nikisch G., and Mathe A.A. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 23 (2008) 356-359
45. Widdowson P.S., Ordway G.A., and Halaris A.E. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 59 (1992) 73-80
46. Miller J.M., Kustra R.P., Vuong A., Hammer A.E., and Messenheimer J.A. Depressive symptoms in epilepsy: Prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 68 (2008) 1493-1509
47. Garry E.M., Delaney A., Anderson H.A., Sirinathsinghji E.C., Clapp R.H., Martin W.J., et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 118 (2005) 97-111
48. Unger J.W., and Lange W. NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: Neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease. Acta Neuropathol 83 (1992) 636-646
49. Arranz B., Blennow K., Ekman R., Eriksson A., Månsson J.E., and Marcusson J. Brain monoaminergic and neuropeptidergic variations in human aging. J Neural Transm 103 (1996) 101-115
50. Escobar C.M., Krajewski S.J., Sandoval-Guzmán T., Voytko M.L., and Rance N.E. Neuropeptide Y gene expression is increased in the hypothalamus of older women. J Clin Endocrinol Metab 89 (2004) 2338-2343
51. Hattiangady B., Rao M.S., Shetty G.A., and Shetty A.K. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp Neurol 195 (2005) 353-371
52. Edvinsson L., Hara H., and Uddman R. Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: Colocalization with different peptides. J Cereb Blood Flow Metab 9 (1989) 212-218
53. Kawamura K., Sakata N., and Takebayashi S. Neuropeptide Y- and vasoactive intestinal polypeptide-containing nerve fibers in the human cerebral arteries: Characteristics of distribution. Angiology 42 (1991) 35-43
54. Tsai S.H., Tew J.M., and Shipley M.T. Development of cerebral arterial innervation: Synchronous development of neuropeptide Y (NPY)-and vasoactive intestinal polypeptide (VIP)-containing fibers and some observations on growth cones. Brain Res Dev Brain Res 69 (1992) 77-83
55. Zardetto-Smith A.M., and Gray T.S. Catecholamine and NPY efferents from the ventrolateral medulla to the amygdala in the rat. Brain Res Bull 38 (1995) 253-260
56. Baraban S.C. Neuropeptide Y and epilepsy: Recent progress, prospects and controversies. Neuropeptides 38 (2004) 261-265
57. Husum H., Bolwig T.G., Sanchez C., Mathe A.A., and Hansen S.L. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: Implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 5 (2004) 204-215
58. Woldbye D.P., and Kokaia M. Neuropeptide Y and seizures: Effects of exogenously applied ligands. Neuropeptides 38 (2004) 253-260
59. Woldbye D.P., Nanobashvili A., Sorensen A.T., Husum H., Bolwig T.G., Sorensen G., et al. Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol Dis 20 (2005) 760-772
60. Lin E.J., Young D., Baer K., Herzog H., and During M.J. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: Evidence from receptor knockout mice. Epilepsia 47 (2006) 773-780
61. Redrobe J.P., Dumont Y., and Quirion R. Neuropeptide Y (NPY) and depression: From animal studies to the human condition. Life Sci 71 (2002) 2921-2937
62. Eva C., Serra M., Mele P., Panzica G., and Oberto A. Physiology and gene regulation of the brain NPY Y1 receptor. Front Neuroendocrinol 27 (2006) 308-339
63. Redrobe J.P., Dumont Y., Herzog H., and Quirion R. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: Evidence from Y2 receptor knockout mice. Behav Brain Res 15 (2003) 251-255
64. Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18 (2003) 143-148
65. Trivedi P.G., Yu H., Trumbauer M., Chen H., Van der Ploeg L.H., and Guan X. Differential regulation of neuropeptide Y receptors in the brains of NPY knock-out mice. Peptides 22 (2001) 395-403
66. Mathew S.J., Price R.B., and Charney D.S. Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. Am J Med Genet C Semin Med Genet 148 (2008) 89-98
67. Wierońska J.M., Smiałowska M., Brański P., Gasparini F., Kłodzińska A., Szewczyk B., et al. In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 29 (2004) 514-521
68. Wierońska J.M., Szewczyk B., Pałucha A., Brański P., Zieba B., and Smiałowska M. Anxiolytic action of Group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacol Rep 57 (2005) 734-743
69. Sergeyev V., Fetissov S., Mathé A.A., Jimenez P.A., Bartfai T., Mortas P., et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology 178 (2005) 115-124
70. Holmes A., Heilig M., Rupniak N.M., Steckler T., and Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24 (2003) 580-588